Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
604 clinical trials found
Clinical trials

HOV156

A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy (NCT04027309)

Currently recruiting

I-MAT

A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma (NCT04291885)

No longer recruiting

IBIS

An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS study (ACTRN12621001037897)

Currently recruiting

IDE196-002

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2) (NCT05987332)

Currently recruiting

IDE196-009

(NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA (NCT05907954)

Currently recruiting

IIHRepurposing1

A phase 2 randomised, placebo- controlled, double-blind pilot trial of drug repurposing in idiopathic intracranial hypertension (ACTRN12625000401459)

Currently recruiting

IKS014-01 IKSUDA

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors (NCT05872295)

Currently recruiting

IMC-F106C-101

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers (NCT04262466)

Currently recruiting

IMC-I109V-101

An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Patients with Chronic HBV who are Non-Cirrhotic, Hepatitis B e Antigen-negative, and Virally Suppressed (ACTRN12620000403932)

Currently recruiting

IMPAHCT

IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in patients with Pulmonary Arterial Hypertension (PAH). (NCT05036135)

Currently recruiting

INCA 33989-101

A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT05936359)

Currently recruiting

INCA035784-101

A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms (NCT07008118)

This is a Phase 1, multicenter, dose-escalation, and dose-expansion study to investigate the safety, tolerability, PK, PD, and preliminary clinical efficacy of INCA035784 in participants with MPN who are positive for CALR exon-9 mutation. This study will involve Q2W dosing with INCA035784. This IP is a T-cell redirecting bispecific antibody that selectively binds to the N-domain of the surface exposed mCALR and CD3 on T cells, designed to redirect CD3 T cells to recognize and eliminate mCALR-expressing malignant cells.
Currently recruiting

INCB 054707-306 STOP-PN2

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis [STOP-PN2] (NCT06516965)

This study is designed to evaluate the effect of povorcitinib on itch and skin lesions in participants with Prurigo Nodularis. Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both taken orally. The treatment period will approximately be 13 months including safety follow up.
Currently recruiting

INCB 161734-101

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160)

Currently recruiting

INCMOR 0208-301

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma (INCMOR0208-301) (NCT04680052)

Currently recruiting

INDEPENDENCE

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (The INDEPENDENCE trial) (NCT04717414)

Currently recruiting

INDEX-AF

The role of pharmacological heart failure therapy in LV recovery following INDEX catheter ablation for atrial fibrillation [AF] induced cardiomyopathy - the INDEX-AF Study (Registration Pending)

Coming soon

INFINITE

A Phase III Randomised Crossover Trial to Assess Feasibility of Domiciliary Nasal High Flow for Chronic Breathlessness in People with Interstitial Lung Disease (ACTRN12623000835640p)

Currently recruiting

INFORMED-1

Integrative approaches for Optimizing Recognition, Management and Education of concussion at the community sports level (ACTRN12623000554662)

Currently recruiting

INI-822-001

A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of INI-822 In Healthy Volunteers And Participants With Non-Alcoholic Steatohepatitis [NASH] Or Presumed NASH (NCT05945537)

Currently recruiting
14 15 16 17 18